Su1376: HIGHER HEPATOCELLULAR CARCINOMA TUMOR BURDEN SCORE IS ASSOCIATED WITH GREATER LIVER TRANSPLANT SURVIVAL BENEFIT

Líu, Hao; Zhang, Wei; Di, Mengyang; Lee, Hang; Cruz, Ruy J.; Wang, Xixi; Kaltenmeier, Christof; Thompson, Ann M.; Reddy, Dheera; Ashwat, Eishan; D'Alesio, Mark; Lebowitz, Steven; Tohme, Samer; Geller, David A.; Tevar, Amit D.; Hughes, Christopher W.; Humar, Abhinav; Behari, Jaideep; Bataller, Ramón; Molinari, Michele

doi:10.1016/s0016-5085(22)63554-6

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies suggest higher tumor burdens might correlate with a more significant transplantation-associated survival benefit despite worse waitlist and post-transplantation survival [42,45]. This counterintuitive result is because the harmful effects of higher tumor burdens are more pronounced in patients on the waitlist than in patients who eventually undergo LT [53], as demonstrated in Figure 2. However, studies on the transplant benefit of HCC vs non-HCC patients yielded contradictory conclusions.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future

Liu,

Sethi,

et al. 2024

Semin Liver Dis

Self Cite

View full text Add to dashboard Cite

Liver transplantation (LT) is a highly effective treatment for carefully selected patients with hepatocellular carcinoma (HCC). In this review, we explored the development of LT selection criteria and organ allocation policies, comparing original data to underscore their historical progression into the intricate task of quantitatively estimating pre- and post-LT survivals. We emphasized the role of biomarkers such as serum AFP, DCP, circulating tumor cells, and circulating tumor DNA in predicting patient outcomes. Additionally, we examined the transplant-associated survival benefits and the difficulties in accurately calculating these benefits. We also reviewed recent advancements in targeted therapy and checkpoint inhibitors for advanced, inoperable HCC and projected their integration into liver transplantation for HCC. We further discussed the growing use of living donor liver transplants in the United States and compared its outcomes with those of deceased donor liver transplants. Furthermore, we examined the progress in machine perfusion techniques, which have shown potential in improving patient outcomes and enlarging the donor pool. These advancements present opportunities to enhance LT patient survivals, refine selection criteria, establish new priority metrics, develop innovative bridging and downstaging strategies, and formulate redesigned LT strategies for HCC treatments.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%